Clinical trials: Chronic Cough
Chronic Obstructive Pulmonary Disease
A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)
A real world study to determine the effectiveness of a patient support service to aid COPD patients in their self management.
- Trial name
- Me&MyCOPD (NCT02300090)
- Testing
- Test Group, Control Group
- Where
- 23 sites in United Kingdom
- Volunteers
- 161 people
- Sponsor
- AstraZeneca
Refractory or Unexplained Chronic Cough
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic…
- Trial name
- ASPIRE (NCT06504446)
- Testing
- NOC-110
- Where
- 106 sites in United States, Belgium and 4 more
- Volunteers
- 455 people
- Sponsor
- Nocion Therapeutics
Refractory Chronic Cough
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- SOOTHE (NCT04678206)
- Testing
- BLU-5937
- Where
- 116 sites in United States, Canada and 5 more
- Volunteers
- 310 people
- Sponsor
- Bellus Health Inc. - a GSK company
Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis
Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine whether lozenges containing interferon-alpha can reduce the frequency and severity of coughing in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
- Trial name
- NCT00690885
- Testing
- interferon-alpha lozenges
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Pulmonary Disease, Chronic Obstructive
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
The study does not involve testing of a drug (no treatment intervention). The study will will use spirometry (breathing tests) in subjects of 40 years of age and older with a history of cigarette smoking with chronic bronchitis…
- Trial name
- NCT00442468
- Testing
- Non-interventional study.
- Where
- 47 sites in United States
- Volunteers
- 1,283 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
- Trial name
- NCT00103922
- Testing
- cilomilast
- Where
- 115 sites in United States
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline
Chronic Cough
A Study of Efficacy and Safety of AX-8 in Chronic Cough
This is a randomized, double-blind, placebo-controlled, crossover, multicenter study of AX-8 in participants with unexplained or refractory chronic cough designed to evaluate the effectiveness of AX-8 in reducing cough frequency.
- Trial name
- NCT04866563
- Testing
- AX-8, Part 1 of the study, AX-8, Part 2 of the study
- Where
- 16 sites in United Kingdom
- Volunteers
- 108 people
- Sponsor
- Axalbion SA
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- OCEAN-1 (NCT07671911)
- Testing
- NAL ER
- Where
- 22 sites in United States
- Volunteers
- 306 people
- Sponsor
- Trevi Therapeutics
Refractory Chronic Cough
A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough
This study is a multicenter, randomized, double-blind, placebo-controlled Phase Ib/II clinical trial to evaluate the effectiveness, safety, tolerability and pharmacokinetics (PK) of TCR1672 Tablets in patients with refractory…
- Trial name
- NCT06213363
- Testing
- TCR1672 tablet
- Volunteers
- 72 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Chronic Cough
A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration
This is a first-in-human study that will investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of HRS-2261 using a double blind, placebo controlled, randomized study design.
- Trial name
- NCT05274516
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pneumonia, Bronchiolitis
Diagnosing Respiratory Disease in Children Using Cough Sounds
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in diagnosis of pneumonia and other respiratory conditions (bronchiolitis, asthma/reactive airway disease, croup, upper or…
- Conditions
- Pneumonia, Bronchiolitis, Asthma, Croup
- Trial name
- SMARTCOUGH-C (NCT02973282)
- Testing
- Recording of Infants and Children's Cough Sounds
- Where
- 3 sites in United States
- Volunteers
- 1,245 people
- Sponsor
- ResApp Health Limited
Refractory Chronic Cough
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.
- Trial name
- LAKE (NCT07671924)
- Testing
- NAL ER
- Where
- 10 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Trevi Therapeutics
Cough
Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)
This is a randomized, double-blind, placebo-controlled, crossover, single center study of SCH 619734 in subjects with chronic cough from an unknown cause.
- Trial name
- NCT00506545
- Testing
- SCH 619734
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Drug Interactions
Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy…
- Trial name
- NCT04252300
- Testing
- Rosuvastatin, Rosuvastatin + BAY1817080
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Cough
Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients
The primary objectives of this study: To investigate the safety and tolerability of ascending repeated oral doses of BAY1902607 in healthy subjects (Part 1).
- Trial name
- NCT03535168
- Testing
- BAY1902607, Midazolam
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 59 people
- Sponsor
- Bayer
Refractory Chronic Cough
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
The primary objective of this double-blind crossover study is to assess the effect of single doses of 50 mg and 300 mg gefapixant (AF-219/MK-7264) on cough reflex sensitivity to capsaicin in both healthy participants and…
- Trial name
- NCT02397460
- Testing
- Gefapixant
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Cough
Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)
This estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (MK-7264) in Japanese adult participants with unexplained or refractory chronic cough.
- Trial name
- NCT03482713
- Testing
- Gefapixant 45 mg
- Where
- 16 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Smoking Cessation
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with…
- Trial name
- NCT01825122
- Testing
- Nadolol
- Where
- 4 sites in United States
- Volunteers
- 155 people
- Sponsor
- Invion, Inc.
Cough
A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
This is an open-label study being conducted in healthy adults, to learn what happens to the study medicine (camlipixant) they are receiving in a person's body over time (a pharmacokinetic [PK] study).
- Trial name
- NCT07684586
- Testing
- Camlipixant
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline